Development to localize endocrine tumors using cell-free DNA obtained from tumor venous blood sampling

Development to localize endocrine tumors using cell-free DNA obtained from tumor venous blood sampling - Localization of endocrine tumors using cell-free DNA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059863

Enrollment

102

Registered

2025-11-23

Start date

2025-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary aldsteronism,or Cushing disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with an endocrinological diagnosis of primary aldosteronism or Cushing's disease who will undergo AVS or IPS/CS sampling for the purpose of localization. 2. Patients aged 18 years or older. 3. Patients who have received a thorough explanation of participation in this study and have provided their voluntary written consent with a full understanding.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating patients 2. Patients in whom it is difficult to collect an additional 5 ml of blood from each of the left and right (or central/peripheral) venous sampling sites 3. Patients who are otherwise deemed inappropriate for this study by the principal investigator.

Design outcomes

Primary

Measure	Time frame
Increace in rate of tumor localization by adding genetic analyses using cell-free DNA obtained from tumor venous sampling in patients with primary aldsteronism or Cushing disease.	—

Countries

Japan

Contacts

Public ContactIchiro Horie

Nagasaki University Hospital Endocrinology and Metabolism

horie@nagasaki-u.ac.jp0958197464

Outcome results